Chicago Equity Partners’s Coherus Oncology CHRS Stock Holding History

Chicago Equity Partners’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$2.39M	Sell	147,255 -164,296	-53%	-$3.04M	0.24%	104
2019 Q4	$5.61M	Buy	311,551 +164,511	+112%	+$3.03M	0.32%	64
2019 Q3	$2.98M	Buy	147,040 +133,360	+975%	+$2.66M	0.14%	213
2019 Q2	$302K	Buy	+13,680	New	+$238K	0.01%	805
2017 Q2	–	Sell	-31,550	Closed	-$667K	–	764
2017 Q1	$667K	Sell	31,550 -25,160	-44%	-$619K	0.02%	538
2016 Q4	$1.6M	Buy	+56,710	New	+$1.59M	0.04%	382

Other funds holding CHRS

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Chicago Equity Partners's CHRS Position: Q1 2020 in Review

Chicago Equity Partners reduced its Coherus Oncology (CHRS) stake by 53% in Q1 2020, selling an estimated $3.04M and leaving 147,255 shares worth $2.39M. The position accounts for 0.24% of the portfolio, ranked #104.

Chicago Equity Partners first reported a position in CHRS in Q4 2016 and has held it in 6 quarters since. The position peaked at $5.61M in Q4 2019. 186 funds tracked by Wall St. Rank hold CHRS as of Q1 2020.

Chicago Equity Partners held 147,255 shares of Coherus Oncology worth $2.39M as of Q1 2020.
Chicago Equity Partners sold 164,296 Coherus Oncology shares in Q1 2020, an estimated $3.04M.
Coherus Oncology made up 0.24% of Chicago Equity Partners's portfolio in Q1 2020, its #104 holding.
Chicago Equity Partners first reported a position in Coherus Oncology in Q4 2016 and has held it in 6 quarters since.
Chicago Equity Partners's Coherus Oncology position peaked at $5.61M in Q4 2019.
186 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.